Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy.
Chiricozzi A, Di Nardo L, Talamonti M, Galluzzo M, De Simone C, Fabbrocini G, Marzano AV, Girolomoni G, Offidani A, Rossi MT, Bianchi L, Cristaudo A, Fierro MT, Stingeni L, Pellacani G, Argenziano G, Patrizi A, Pigatto P, Romanelli M, Savoia P, Rubegni P, Foti C, Milanesi N, Belloni Fortina A, Bongiorno MR, Grieco T, Di Nuzzo S, Fargnoli MC, Carugno A, Motolese A, Rongioletti F, Amerio P, Balestri R, Potenza C, Micali G, Patruno C, Zalaudek I, Lombardo M, Feliciani C, Antonelli F, Ferrucci SM, Guarneri F, Peris K.
Chiricozzi A, et al. Among authors: potenza c.
Dermatitis. 2022 May-Jun 01;33(3):e25-e29. doi: 10.1097/DER.0000000000000814. Epub 2021 Dec 10.
Dermatitis. 2022.
PMID: 35129461
Free PMC article.
No abstract available.